Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2020-07-03 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related capital changes for the month ended 30/06/2020. The content focuses on share capital changes and confirmations related to securities issuance, with no financial performance data, earnings, or management discussion. It is a regulatory filing reporting share capital movements rather than a financial report or announcement of voting results. Therefore, it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement about share capital movements.
2020-07-03 English
INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a placing of existing shares by a controlling shareholder. It includes details about the number of shares placed, the shareholding percentages before and after the placing, and references to regulatory rules under the Hong Kong Stock Exchange. The document is relatively short (3208 characters) and serves as a notification of a capital market transaction rather than a detailed financial report or analysis. It does not contain financial statements or management discussion, nor is it a report publication or certification. The content fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2020-06-16 English
INSIDE INFORMATION ANNOUNCEMENT - PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the placing of existing shares by a controlling shareholder of Alphamab Oncology. It details the share placing agreement, lock-up undertakings, completion timeline, and changes in shareholding percentages. There is no financial data, earnings information, or detailed report content. The document is a regulatory announcement about a share transaction by a controlling shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is 6847 characters, which is sufficient for a full announcement, not a brief note or a report publication announcement. Therefore, the classification is MRQ with high confidence.
2020-06-12 English
VOLUNTARY ANNOUNCEMENT - CO-DEVELOPMENT OF ANTIBODY FOR CORONAVIRUS TREATMENT WITH INSTITUT PASTEUR OF SHANGHAI
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding a new co-development agreement with Institut Pasteur of Shanghai for antibody treatment targeting coronavirus. It details the terms of the collaboration, responsibilities of each party, profit distribution, and background information about the parties involved. There are no financial statements, quarterly or annual results, or regulatory certifications present. The document is an announcement of a business development and partnership rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification either. The content clearly aligns with a Capital/Financing Update (CAP) as it relates to a significant business collaboration and development agreement that could impact the company's future capital and operations. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-06-10 English
VOLUNTARY ANNOUNCEMENT - STRATEGIC COLLABORATION WITH SANOFI ON KN026 IN HER2+ BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding a strategic collaboration with Sanofi on a drug candidate KN026. It details the terms of the collaboration, background on the drug, clinical trials, and company information. There are no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no detailed financial or governance reports. The document is an announcement of a business development event rather than a formal financial or regulatory filing. It is not a report publication announcement since it contains substantive information about the collaboration. The best fitting category is a general regulatory announcement about business developments, which falls under Regulatory Filings (RNS).
2020-06-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, including authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 31/05/2020. It is addressed to the Hong Kong Exchanges and Clearing Limited, indicating a regulatory filing related to share capital changes. The content focuses on share capital movements, share options exercised, and confirmations related to securities issued. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is not a report publication announcement but a substantive regulatory disclosure. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2020-06-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.